Skip to main
HROW
HROW

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow Inc has demonstrated significant growth in its pharmaceutical sales, with total revenue increasing from $88.6 million in 2022 to $130.2 million in 2023, representing a 47% year-over-year increase. The company's new product VEVYE, launched in January 2024, surpassed management's expectations with a 55% increase in prescription volume in the third quarter of 2024, generating $5.2 million in sales. Additionally, IHEEZO has experienced remarkable growth, with unit sales soaring from 6,471 in the third quarter of 2023 to 34,468 in the third quarter of 2024, resulting in $12.9 million in revenue for the latest quarter.

Bears say

Harrow Inc. is facing a challenging financial landscape characterized by a recent decline in operating income and adjusted EBITDA despite a temporary recovery in the second and third quarters of 2024. The company's smaller size and limited financial resources hinder its ability to capture substantial market share, compounded by regulatory changes and biotechnology advancements that could render its products uncompetitive. Additionally, risks such as difficulties in new product integration, maintaining healthy cash flows, serviceability of $216 million in outstanding debt, and potential regulatory non-compliance pose significant threats to Harrow's growth and profitability outlook.

HROW has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 6 analysts, HROW has a Strong Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.